• Offices & Administration
• About LDH
• LDH News

LDH News

• December 10, 2019

  Louisiana Department of Health and Walmart collaborate to offer free screenings for hepatitis C

  The Louisiana Department of Health (LDH) announced a new collaboration with Walmart to advance the state’s goal of eliminating hepatitis C in Louisiana by 2024. LDH and Walmart will work together to implement a pilot program in 10 Walmart stores to offer free hepatitis C screenings at the pharmacy for people who are at risk, along with in-store education and awareness. The free screenings will begin on Dec. 11 and will be offered from 2 – 6 p.m. each Wednesday in-store until Feb. 1, 2020.

• December 05, 2019

  State’s innovative payment agreement with Asegua Therapeutics for hepatitis C medication allows more Louisianans to receive life-saving treatment

  More Louisiana residents living with hepatitis C have been able to receive life-saving treatment because of Louisiana’s innovative payment model for the medications that cure this illness.

• August 15, 2019

  Louisiana Departments of Health and Corrections seeking feedback on Louisiana Hepatitis C Elimination plan

  This comprehensive, evidence-based and action-oriented plan seeks to guide efforts to achieve elimination of the virus as a public health threat in Louisiana by the end of 2024.

• July 16, 2019

  Media Advisory: Department of Health’s Hepatitis C elimination strategy underway – Patients now have access to curative medications

  Media is invited to join state officials, a Care South Clinic physician and a patient as the Department of Health begins its hepatitis C elimination strategy.

• June 26, 2019

  CMS Approves Louisiana State Plan Amendment for Supplemental Rebate Agreements Using a Modified Subscription Model for Hepatitis C Therapies in Medicaid

  Today the Centers for Medicare and Medicaid Services (CMS) approved Louisiana’s Medicaid State Plan Amendment (SPA) authorizing the state to negotiate supplemental rebate agreements from prescription drug manufacturers. The SPA permits the state to negotiate supplemental rebate agreements using a new “modified subscription” model that initially focuses on antiviral agents for hepatitis C and that promotes eliminating the hepatitis C virus statewide.

• June 26, 2019

  Louisiana launches hepatitis C innovative payment model with Asegua Therapeutics, aiming to eliminate the disease

  “This new model has the potential to save many lives and improve the health of our citizens. It is an important day for our state, for our partner Asegua Therapeutics, for providers, but most importantly for the patients and their families who will benefit from treatment,” said Governor Edwards.

• May 01, 2019

  More states follow Louisiana’s hepatitis C subscription model

• April 01, 2019

  HEALTH AFFAIRS: Louisiana’s journey toward eliminating hepatitis C

  Hepatitis C is the leading infectious disease killer of our time, but it is also one of the few viruses that has a cure—direct-acting antiviral medications. Several years ago, Louisiana set out to eliminate the disease to reduce preventable suffering and premature death.

• March 26, 2019

  Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model

  The Department of Health and Department of Corrections will now establish a contract with Asegua Therapeutics to make its medication, the authorized generic of Epclusa® (sofosbuvir/velpatasvir tablets), available to hepatitis C patients enrolled in Medicaid and to treat incarcerated patients over the next five years.

• March 01, 2019

  Department of Health receives three proposals for hepatitis C payment model

  Dr. Rebekah Gee, secretary of the Louisiana Department of Health, said that having three pharmaceutical companies submit a response means the State is one giant step closer to its goal of eliminating hepatitis C in Louisiana.

• January 11, 2019

  Why Louisiana is pursuing Netflix-style payments for hepatitis C treatments

• January 10, 2019

  Louisiana proceeds with plans for a ‘Netflix’ subscription model to buy hepatitis C drugs